Neonatal HypothermiaNCT03965312
Pilot Clinical Assessment of Low-cost Infant Incubator in Monitoring Temperature and Treating Hypothermia in Infants
A study testing Continuous temperature monitor, Neonatal Incubator and Patient monitor in people with Neonatal Hypothermia, run by William Marsh Rice University at 1 site in Malawi.
Trial summary
A team of researchers at Rice University and Queen Elizabeth Central Hospital (QECH) are working to develop a low-cost infant incubator called "IncuBaby" that consists of two components: a temperature sensor that can continuously monitor an infant's temperature, and a heated, enclosed area that can adjust internal… Read more about this study
- Who is it for?
- Ages Up to 28 days
- Conditions the study is for
- Neonatal Hypothermia
- What is being tested?
- Continuous temperature monitor, Neonatal Incubator and Patient monitor
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteMalawi
- Study dates
- 31 Jul 2017to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 28 days
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- The subject is currently being treated at QECH in the neonatal ward.
- An IncuBaby device and study monitor are available for use.
- The subject's caregiver has provided informed consent for their child to participate (consent form attached to this proposal).
- Phase II only: the subject is eligible for thermal care in an incubator. If the subject is recommended for KMC, they will not be eligible for participation in this study. To be considered for care with the IncuBaby, infants should be:
- Less than 1000 g
- Or > 1000 g but
Show all 12Show fewer
- Receiving medical interventions such as CPAP, oxygen, phototherapy, or IV
- Unstable, critically ill or surgical conditions
- No mother or caregiver available for KMC
- Mother too sick to provide KMC
- Clinician in charge has decided against KMC as requires closer supervision by nursing staff
- No space in KMC
Who cannot join
- The subject may be excluded from the study at the clinician's discretion for any reason including potential for skin irritation, cough or other condition that may preclude use of the temperature belt, or concurrent treatments that may require increased patient care. Only subjects eligible for care in an incubator will be enrolled in phase II.
Trial locations and contacts
1 site in 1 country.
Malawi1 site, 1 recruiting
- Recruiting
Queen Elizabeth Central Hospital
Blantyre
Rebecca R Richards-Kortum, PhD, 7133483823, rkortum@rice.edu
Queen Dube, MD, drdubefirst@yahoo.com
About this study
A team of researchers at Rice University and Queen Elizabeth Central Hospital (QECH) are working to develop a low-cost infant incubator called "IncuBaby" that consists of two components: a temperature sensor that can continuously monitor an infant's temperature, and a heated, enclosed area that can adjust internal temperature based on the feedback from the temperature sensor. This robust, low-cost device will allow for the individualized treatment of hypothermia with minimal intervention from the clinical staff. In this study, researchers intend to evaluate the efficacy of this incubator at QECH by comparing infants' temperatures before and after treatment, and calculating the proportion of time that the infants remain in a normothermic range after rewarming. During phase I of this study, the infants will be continuously monitored using the IncuBaby temperature sensor and a gold standard temperature monitor for up to 3 days. The accuracy of the IncuBaby temperature sensor will be determined by calculating the difference between the temperatures recorded by the temperature sensor and the commercial patient monitor at each point in time. During phase II of the study, infants in need of thermal care with an incubator will be treated with an IncuBaby device and their temperatures will be continuously monitored by both the temperature sensor of the IncuBaby device and a commercially available patient monitor. Care will continue at the clinician's discretion until the infant can be weaned from the incubator or until patients are withdrawn from the study and placed on the standard of care. To determine the effectiveness of the IncuBaby device at warming infants, the temperatures of the infants will be compared before and after treatment for each subject. The proportion of time the device maintains the subject's temperature in a normal range will also be calculated.
Read the detailed description
This is a two-phase, pilot prospective study to determine the effectiveness of a low-cost incubator in warming infants and regulating their temperatures. The temperature sensor that controls the heat of the incubator based on the infant's temperature has been previously evaluated in Rice IRB approved studies in Houston, TX with plans to evaluate at QECH. The first phase will validate the use of the temperature sensor in infants by comparing it to a commercial temperature monitor. The second phase will test the effectiveness of the IncuBaby device using that temperature sensor to regulate the heat of the infant.
Treatment and Monitoring of Neonates
During Phase I, the following steps will be taken:
A trained study nurse will assess the subject for clinical complications before attaching the temperature monitoring device.
A trained study nurse or clinician will attach the temperature monitoring device to the infant. A trained research assistant from Rice University or from the Biomedical Engineering Department at Malawi Polytechnic will observe all procedures and will notify the nurse of any observed errors so they may be corrected. They will also be able to answer any technical questions from the nurse.
The trained study nurse will attach the temperature probe from the commercial patient monitor as well as provide any other care needed.
A research assistant will use a laptop to collect the electrical signals from both temperature monitors.
Temperature monitoring will continue for up to 3 days. The research assistant may ask the nurse to remove and reapply the temperature monitor during this period.
Upon removal of the abdominal strap at the end of the study, the subject may be monitored for up to one hour in order to assess the effect of the abdominal strap on the skin of the subject.
Once Phase I is complete, Phase II will begin. During Phase II, the following steps will be taken:
A trained study nurse will assess the subject for clinical complications before beginning treatment.
A trained study nurse or research technician will turn the incubator on to begin pre-warming.
A trained study nurse or clinician will attach the temperature probe from the IncuBaby device to the infant and then place the infant in the incubator. A trained research assistant from Rice University or from the Biomedical Engineering Department at Malawi Polytechnic will observe all procedures and will notify the nurse of any observed errors so they may be corrected. They will also be able to answer any technical questions from the nurse.
The trained study nurse will attach the temperature probe from the commercial patient monitor as well as provide any other care needed.
A research assistant will use a laptop to collect the data from both devices.
Care will be continued at the discretion of the clinician until the infant can be weaned from the IncuBaby device. The infant may be weaned to the standard of care or end thermal treatment. The infant will be transitioned to KMC as soon as possible after these eligibility criteria are fulfilled:
Completed other treatment (CPAP, phototherpay, IV) Mom/caregiver becomes available Weight increases > 1000 g Becomes clinically stable Body temperture is stable and not dipping below normal despite thermal support
Based on the discretion of the clinician, the subject may be weaned to KMC or an open cot. The IncuBaby device has a "weaning" setting that turns off the heaters in the incubator but continues to monitor the infant's temperature. If the infant is found to be hypothermic after ending treatment and the clinician recommends continued incubator care, the subject may recommence use of the IncuBaby for treatment.
The commercial patient monitor will alert nursing staff if the baby's temperature becomes too high or too low. Temperature settings for alarms will be set by a clinician so that the high temperature alarm is > 37.5 C, and the low temperature alarm is < 36.5 C. During Phase II, the following steps will be recommended if the commercial patient monitor sounds a high or low temperature alarm. These guidelines were written in accordance with current clinical practice at QECH. The study nurse can also choose to discontinue the use of the IncuBaby device at any time.
High temperature alarm - indicates possible hyperthermia Check that the incubator temperature is at 36C or less. Open the incubator and recheck the baby's temperature If baby's temperature is still above normal remove blankets/clothing If baby is febrile despite these measures look for a clinical reason for the temperature Remove the infant from the IncuBaby device Low temperature alarm - indicates possible hypothermia
Check that the incubator is in on and functioning Check that the temperature probe has not fallen off. Recheck the baby's temperature If temperature still low add blankets/clothing and hat If the temperature is still low look for a clinical reason for the hypothermia
During both phases, a research assistant will be available during the trial to mitigate any complications with the device. A nurse will be available to respond to alarms from the continuous patient monitor. If the subject's guardian, the nurse, or the research assistant indicates concern during the tests, the study treatment can be discontinued and the subject will return to the standard of care.
Intended Data Collection:
Clinical data will be collected on paper forms as is consistent with current clinical practice. Data will be saved on a secure study server for analysis. Clinical and/or research personnel will record information, excluding personal identifiers, on a standardized patient monitoring form. After the subject's participation is complete, a research assistant will collect and scan the form. We will collect the following information:
- Baseline demographic and relevant medical information
- Recorded one at enrollment i. Date of study ii. Date of birth iii. Sex iv. Birth weight v. Type of delivery vi. Gestational age at birth vii. Corrected gestational age viii. Abdominal circumference ix. Admission temperature b. Recorded throughout study as clinically collected i. Other comorbidities ii. Medications/treatments given iii. Current weight iv. Temperature measurements taken as standard of care
- Accuracy a. Recorded automatically by study equipment i. Abdominal temperature from IncuBaby temperature probe and gold standard device ii. Alarms iii. Temperature in incubator* b. CO2 levels c. Humidity levels in the incubator d. Movement/other caregiving e. Fit/tightness of the strap during and/or at end of study f. Ambient temperature g. Routine assessment of abdominal skin (i.e. indentation, skin irritation) h. Strap site assessment during and/or at end of study i. Commercially available patient monitor temperature sensor site assessment during and/or at end of study j. Nurse comments k. Research technicians comments
- Phase II only, if enclosed A log of an observed user error or comments about the device will be used to improve future iterations of the device. The nurse and technician monitoring forms that will be used to record the above variables are attached to this proposal.
- Conditions
- Neonatal Hypothermia
- Being tested
- Continuous temperature monitor, Neonatal Incubator, Patient monitor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous temperature monitorDevice
Also called IncuBaby temperature sensor and monitor, Neonatal temperature monitor
Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
Neonatal IncubatorDevice
Also called IncuBaby
Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
Patient monitorDevice
Also called Philips Intellivue patient monitor
Temperature will be measured using a commercially available patient monitor.
| Study group | Role | What they receive |
|---|---|---|
| Temperature monitoring (1) and incubator test (2) groups | Experimental | In the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours.
In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator. Receives: Device: Continuous temperature monitor; Device: Neonatal Incubator; Device: Patient monitor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Temperature monitor accuracy
Continuously measured temperature for temperature monitor compared against Philips Intellivue patient monitor
Measured: from time of enrollment until intervention is complete; up to 28 days
Temperature of incubator
Continuously measured temperature of incubator
Measured: from time of enrollment until intervention is complete; up to 28 days
Temperature of infant
Continuously measured temperature of infant
Measured: from time of enrollment until intervention is complete; up to 28 days
Secondary outcomes (2)
Time until normothermia
Time until infant becomes normothermic (36.5-37.5C)
Measured: from time of enrollment until intervention is complete; up to 28 days
Proportion of time normothermic
The proportion of treatment time that the infant is normothermic (36.5-37.5C)
Measured: from time of enrollment until intervention is complete; up to 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2019
- Study start31 Jul 2017
- Primary completion30 Sep 2022 (estimated)
- Study completion30 Sep 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Neonatal HypothermiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- In the first phase of the study, a novel neonatal temperature monitor and a commercially available patient monitor (Philips Intellivue MP30) will be applied to the same infant; results between them will be compared. In the second phase of the study, infants at risk for hypothermia will be placed in an infant incubator; the accuracy of the temperature sensor, time required for infant to become normothermic, and the proportion of time that the infant remains normothermic will be measured.
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- William Marsh Rice University
- Sponsor type
- University, hospital or other
- Collaborators
- Kamuzu University of Health Sciences
- Responsible party
- Sponsor
- Investigators
- Rebecca Richards-Kortum, PhD, Principal investigator, William Marsh Rice UniversityQueen Dube, MD, Principal investigator, Kamuzu University of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03965312
- Sponsor's protocol ID
- IncuBaby-NHSRC
- Status last verified
- Sep 2021
- First submitted
- 31 Jan 2019
- Last updated
- 21 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sosa Saenz SE, Hardy MK, Heenan M, Oden ZM, Richards-Kortum R, Dube Q, Kawaza K. Evaluation of a continuous neonatal temperature monitor for low-resource settings: a device feasibility pilot study. BMJ Paediatr Open. 2020 May 7;4(1):e000655. doi: 10.1136/bmjpo-2020-000655. eCollection 2020.
PubMed 32426530
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Clinical Assessment of Low-cost Infant Incubator in Monitoring Temperature and Treating Hypothermia in Infants
- ClinicalTrials.gov ID
- NCT03965312
- Acronym / sponsor ID
- IncuBaby-NHSRC
- Conditions
- Neonatal Hypothermia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- William Marsh Rice UniversityUniversity, hospital or other
- Collaborators
- Kamuzu University of Health Sciences
- Study start
- 31 Jul 2017 (actual)
- Primary completion
- 30 Sep 2022 (estimated)
- Study completion
- 30 Sep 2022 (estimated)
- First posted
- 29 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A team of researchers at Rice University and Queen Elizabeth Central Hospital (QECH) are working to develop a low-cost infant incubator called "IncuBaby" that consists of two components: a temperature sensor that can continuously monitor an infant's temperature, and a heated, enclosed area that can adjust internal temperature based on the feedback from the temperature sensor. This robust, low-cost device will allow for the individualized treatment of hypothermia with minimal intervention from the clinical staff. In this study, researchers intend to evaluate the efficacy of this incubator at QECH by comparing infants' temperatures before and after treatment, and calculating the proportion of time that the infants remain in a normothermic range after rewarming. During phase I of this study, the infants will be continuously monitored using the IncuBaby temperature sensor and a gold standard temperature monitor for up to 3 days. The accuracy of the IncuBaby temperature sensor will be determined by calculating the difference between the temperatures recorded by the temperature sensor and the commercial patient monitor at each point in time. During phase II of the study, infants in need of thermal care with an incubator will be treated with an IncuBaby device and their temperatures will be continuously monitored by both the temperature sensor of the IncuBaby device and a commercially available patient monitor. Care will continue at the clinician's discretion until the infant can be weaned from the incubator or until patients are withdrawn from the study and placed on the standard of care. To determine the effectiveness of the IncuBaby device at warming infants, the temperatures of the infants will be compared before and after treatment for each subject. The proportion of time the device maintains the subject's temperature in a normal range will also be calculated.
Detailed description
This is a two-phase, pilot prospective study to determine the effectiveness of a low-cost incubator in warming infants and regulating their temperatures. The temperature sensor that controls the heat of the incubator based on the infant's temperature has been previously evaluated in Rice IRB approved studies in Houston, TX with plans to evaluate at QECH. The first phase will validate the use of the temperature sensor in infants by comparing it to a commercial temperature monitor. The second phase will test the effectiveness of the IncuBaby device using that temperature sensor to regulate the heat of the infant.
Treatment and Monitoring of Neonates
During Phase I, the following steps will be taken:
A trained study nurse will assess the subject for clinical complications before attaching the temperature monitoring device.
A trained study nurse or clinician will attach the temperature monitoring device to the infant. A trained research assistant from Rice University or from the Biomedical Engineering Department at Malawi Polytechnic will observe all procedures and will notify the nurse of any observed errors so they may be corrected. They will also be able to answer any technical questions from the nurse.
The trained study nurse will attach the temperature probe from the commercial patient monitor as well as provide any other care needed.
A research assistant will use a laptop to collect the electrical signals from both temperature monitors.
Temperature monitoring will continue for up to 3 days. The research assistant may ask the nurse to remove and reapply the temperature monitor during this period.
Upon removal of the abdominal strap at the end of the study, the subject may be monitored for up to one hour in order to assess the effect of the abdominal strap on the skin of the subject.
Once Phase I is complete, Phase II will begin. During Phase II, the following steps will be taken:
A trained study nurse will assess the subject for clinical complications before beginning treatment.
A trained study nurse or research technician will turn the incubator on to begin pre-warming.
A trained study nurse or clinician will attach the temperature probe from the IncuBaby device to the infant and then place the infant in the incubator. A trained research assistant from Rice University or from the Biomedical Engineering Department at Malawi Polytechnic will observe all procedures and will notify the nurse of any observed errors so they may be corrected. They will also be able to answer any technical questions from the nurse.
The trained study nurse will attach the temperature probe from the commercial patient monitor as well as provide any other care needed.
A research assistant will use a laptop to collect the data from both devices.
Care will be continued at the discretion of the clinician until the infant can be weaned from the IncuBaby device. The infant may be weaned to the standard of care or end thermal treatment. The infant will be transitioned to KMC as soon as possible after these eligibility criteria are fulfilled:
Completed other treatment (CPAP, phototherpay, IV) Mom/caregiver becomes available Weight increases > 1000 g Becomes clinically stable Body temperture is stable and not dipping below normal despite thermal support
Based on the discretion of the clinician, the subject may be weaned to KMC or an open cot. The IncuBaby device has a "weaning" setting that turns off the heaters in the incubator but continues to monitor the infant's temperature. If the infant is found to be hypothermic after ending treatment and the clinician recommends continued incubator care, the subject may recommence use of the IncuBaby for treatment.
The commercial patient monitor will alert nursing staff if the baby's temperature becomes too high or too low. Temperature settings for alarms will be set by a clinician so that the high temperature alarm is > 37.5 C, and the low temperature alarm is < 36.5 C. During Phase II, the following steps will be recommended if the commercial patient monitor sounds a high or low temperature alarm. These guidelines were written in accordance with current clinical practice at QECH. The study nurse can also choose to discontinue the use of the IncuBaby device at any time.
High temperature alarm - indicates possible hyperthermia Check that the incubator temperature is at 36C or less. Open the incubator and recheck the baby's temperature If baby's temperature is still above normal remove blankets/clothing If baby is febrile despite these measures look for a clinical reason for the temperature Remove the infant from the IncuBaby device Low temperature alarm - indicates possible hypothermia
Check that the incubator is in on and functioning Check that the temperature probe has not fallen off. Recheck the baby's temperature If temperature still low add blankets/clothing and hat If the temperature is still low look for a clinical reason for the hypothermia
During both phases, a research assistant will be available during the trial to mitigate any complications with the device. A nurse will be available to respond to alarms from the continuous patient monitor. If the subject's guardian, the nurse, or the research assistant indicates concern during the tests, the study treatment can be discontinued and the subject will return to the standard of care.
Intended Data Collection:
Clinical data will be collected on paper forms as is consistent with current clinical practice. Data will be saved on a secure study server for analysis. Clinical and/or research personnel will record information, excluding personal identifiers, on a standardized patient monitoring form. After the subject's participation is complete, a research assistant will collect and scan the form. We will collect the following information:
- Baseline demographic and relevant medical information
- Recorded one at enrollment i. Date of study ii. Date of birth iii. Sex iv. Birth weight v. Type of delivery vi. Gestational age at birth vii. Corrected gestational age viii. Abdominal circumference ix. Admission temperature b. Recorded throughout study as clinically collected i. Other comorbidities ii. Medications/treatments given iii. Current weight iv. Temperature measurements taken as standard of care
- Accuracy a. Recorded automatically by study equipment i. Abdominal temperature from IncuBaby temperature probe and gold standard device ii. Alarms iii. Temperature in incubator* b. CO2 levels c. Humidity levels in the incubator d. Movement/other caregiving e. Fit/tightness of the strap during and/or at end of study f. Ambient temperature g. Routine assessment of abdominal skin (i.e. indentation, skin irritation) h. Strap site assessment during and/or at end of study i. Commercially available patient monitor temperature sensor site assessment during and/or at end of study j. Nurse comments k. Research technicians comments
- Phase II only, if enclosed A log of an observed user error or comments about the device will be used to improve future iterations of the device. The nurse and technician monitoring forms that will be used to record the above variables are attached to this proposal.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- In the first phase of the study, a novel neonatal temperature monitor and a commercially available patient monitor (Philips Intellivue MP30) will be applied to the same infant; results between them will be compared. In the second phase of the study, infants at risk for hypothermia will be placed in an infant incubator; the accuracy of the temperature sensor, time required for infant to become normothermic, and the proportion of time that the infant remains normothermic will be measured.
| Arm | Type | Receives |
|---|---|---|
| Temperature monitoring (1) and incubator test (2) groups | Experimental | Device: Continuous temperature monitor, Device: Neonatal Incubator, Device: Patient monitorIn the first (1) phase of the study, the temperature probe and monitor will be attached to infants along with the Philips Intellivue patient monitor. Temperature will be monitored continuously for up to 72 hours. In the second (2) phase of this study, infants at risk for hypothermia and not eligible for skin-to-skin care will be placed in the incubator. |
Who may qualify
- Ages
- Up to 28 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (12 listed)
- The subject is currently being treated at QECH in the neonatal ward.
- An IncuBaby device and study monitor are available for use.
- The subject's caregiver has provided informed consent for their child to participate (consent form attached to this proposal).
- Phase II only: the subject is eligible for thermal care in an incubator. If the subject is recommended for KMC, they will not be eligible for participation in this study. To be considered for care with the IncuBaby, infants should be:
Key exclusion criteria (1 listed)
- The subject may be excluded from the study at the clinician's discretion for any reason including potential for skin irritation, cough or other condition that may preclude use of the temperature belt, or concurrent treatments that may require increased patient care. Only subjects eligible for care in an incubator will be enrolled in phase II.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous temperature monitorAlso: IncuBaby temperature sensor and monitor, Neonatal temperature monitorTemperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated. | Device | Temperature monitoring (1) and incubator test (2) groups |
| Neonatal IncubatorAlso: IncuBabyInfants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia. | Device | Temperature monitoring (1) and incubator test (2) groups |
| Patient monitorAlso: Philips Intellivue patient monitorTemperature will be measured using a commercially available patient monitor. | Device | Temperature monitoring (1) and incubator test (2) groups |
Primary outcome
Temperature monitor accuracy
Time frame: from time of enrollment until intervention is complete; up to 28 days
Continuously measured temperature for temperature monitor compared against Philips Intellivue patient monitor
Temperature of incubator
Time frame: from time of enrollment until intervention is complete; up to 28 days
Continuously measured temperature of incubator
Temperature of infant
Time frame: from time of enrollment until intervention is complete; up to 28 days
Continuously measured temperature of infant
2 secondary outcomes
Time until normothermia
Time frame: from time of enrollment until intervention is complete; up to 28 days
Proportion of time normothermic
Time frame: from time of enrollment until intervention is complete; up to 28 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2021.
- Derived from this study: PubMed 32426530Sosa Saenz SE, Hardy MK, Heenan M, Oden ZM, Richards-Kortum R, Dube Q, Kawaza K. Evaluation of a continuous neonatal temperature monitor for low-resource settings: a device feasibility pilot study. BMJ Paediatr Open. 2020 May 7;4(1):e000655. doi: 10.1136/bmjpo-2020-000655. eCollection 2020.
- Individual participant dataSharing planned: No
Related trials for Neonatal Hypothermia
RecruitingPhase 2
The PROTECT-HIE Pilot Trial
Hypoxic-ischemic Encephalopathy (HIE)
RecruitingPhase 2/3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
Hypoxic-Ischemic Encephalopathy
Not yet recruiting
Levetiracetam as an Adjuvant Therapy to Hypothermia in Neonatal Asphyxia
Hypoxic Ischemic Encephalopathy of Newborn, Neuro-protection
RecruitingObservational study
Continuous Monitoring of Body Temperature in Neonates During Therapeutic Hypothermia
Therapeutic Hypothermia, Neonatal Hypoxic-Ischemic Encephalopathy
Active, not recruiting
Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part I
Hypothermia, Immature Newborn
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rebecca Richards-Kortum, PhD principal investigator
William Marsh Rice University
Queen Dube, MD principal investigator
Kamuzu University of Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous temperature monitor, Neonatal Incubator and Patient monitor in people with Neonatal Hypothermia, run by William Marsh Rice University at 1 site in Malawi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malawi. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rebecca Elias, MPH (713-348-6574, rebecca.elias@rice.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Temperature monitor accuracy (time frame: from time of enrollment until intervention is complete; up to 28 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03965312, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2021.